Acarbose
Precose (acarbose) is an oligosaccharide pharmaceutical. Acarbose was first approved as Precose on 1995-09-06. It is used to treat type 2 diabetes mellitus in the USA. It is known to target maltase-glucoamylase and pancreatic alpha-amylase.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acarbose
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRECOSE | Bayer | N-020482 DISCN | 1995-09-06 | 3 products, RLD |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
HCPCS
No data
Clinical
Clinical Trials
89 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 2 | 10 | 27 | 9 | 52 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | 3 | 8 | 12 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 5 | 1 | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 2 | 1 | 3 |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | 2 | — | 3 | |
| Healthy volunteers/patients | — | 1 | — | — | 1 | — | 2 | ||
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | 1 | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | 1 | — | 1 |
| Heart disease risk factors | D000082742 | — | — | — | 1 | — | 1 | ||
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glucose metabolism disorders | D044882 | — | — | 1 | — | 1 | 2 | ||
| Gestational diabetes | D016640 | HP_0009800 | O24.4 | — | — | 1 | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overweight | D050177 | E66.3 | 1 | 1 | — | — | 1 | 2 | |
| Hypotension | D007022 | EFO_0005251 | I95 | — | 2 | — | — | — | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 2 | — | — | — | 2 |
| Syncope | D013575 | HP_0001279 | G90.01 | — | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 2 | 2 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 1 | 1 | |
| Abdominal pain | D015746 | R10.9 | — | — | — | — | 1 | 1 | |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 1 | 1 |
| Exocrine pancreatic insufficiency | D010188 | K86.81 | — | — | — | — | 1 | 1 | |
| Endoscopic retrograde cholangiopancreatography | D002760 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ACARBOSE |
| INN | acarbose |
| Description | (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol is a glycoside and an amino cyclitol. |
| Classification | Oligosaccharide |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 56180-94-0 |
| RxCUI | 16681 |
| ChEMBL ID | CHEMBL1566 |
| ChEBI ID | — |
| PubChem CID | 444254 |
| DrugBank | DB00284 |
| UNII ID | T58MSI464G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MGAM
MGAM
AMY2A
AMY2A
Organism
Homo sapiens
Gene name
MGAM
Gene synonyms
MGA, MGAML
NCBI Gene ID
Protein name
maltase-glucoamylase
Protein synonyms
Alpha-1,4-glucosidase, brush border hydrolase, maltase-glucoamylase (alpha-glucosidase), maltase-glucoamylase, intestinal
Uniprot ID
Mouse ortholog
Mgam (232714)
maltase-glucoamylase (A0A571BF69)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,776 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more